On October 15, Axinn partner Chad Landmon moderated a panel entitled, "Advertising and Promotion of Reference and Biosimilar Products—Where are We Now?" at the virtual FDLI 2021 Advertising and Promotion for Medical Products Conference.

This session examined how FDA guidance has impacted the industry’s decision-making around entering the reference and biosimilar product markets. The panel also gauged how interchangeable-specific issues are playing out and whether additional solutions may be needed.

Click here for more information.